UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):

April 16th, 2020

 

CANNABICS PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

Nevada 333-192759 20-3373669
(State of incorporation) (Commission File Number) (IRS Employer No.)

 

#3 Bethesda Metro Center

Suite 700

Bethesda, Md 20814

(Address of principal executive offices and Zip Code)

 

877 424-2429

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

☐      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
Common Stock, par value $0.0001 per share   CNBX   OTCQB

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   ☐         

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

     

 

 

ITEM 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

 

On April 16th, 2020, the Board of Directors nominated fellow Director and Board Member Itamar Borochov as Chairman of the Board; at the same time the Board nominated fellow Director and Board Member Gabriel Yariv as President of the Corporation.

 

Mr. Itamar Borochov, 62, is an environmentalist with vast experience as an entrepreneur in the medical cannabis field, with broad experience in management, finance and regulated medical cannabis companies. Mr. Borochov was the original Founder of Cannabics Pharmaceuticals Inc.

 

Mr. Yariv, 43, brings over 20 years of successful executive experience in the medical industry. Mr. Yariv was part of the founding group of BreathID., an Oridion Medical business unit (now Medtronic) and its subsequent spinoff company, BreathID Inc., (now Exalenz Bioscience) develops and manufactures advanced non-invasive diagnostic medical devices for gastrointestinal and liver conditions. Mr. Yariv also co-founded SimuTec, a medical simulation and training company in Brazil that develops and commercializes advanced personalized Virtual Reality training programs for physicians.

 

Mr. Yariv is actively engaged in non-profit and philanthropic activities including ongoing business mentoring of entrepreneurs, founder of the Yariv Foundation for Leadership, and current member of the Friends of the Israel Museum society. Mr. Yariv holds a BA (Cum Laude) in History, Philosophy & Political science from Boston University, and a Certificate Course in Cyberlaw from Harvard University ES.

 

Exhibit

Number

Description
   
10.1 Board of Director’s Resolution Appointing Itamar Borochov as Chairman of the Board.
10.2 Board of Director’s Resolution Appointing Gabriel Yariv as President of the Company.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated: April 16th, 2020 CANNABICS PHARMACEUTICALS, INC.
     
  By: /s/ Eyal Barad
  Name: Eyal Barad
  Title: Chief Executive Officer

 

 

 

 

 

 

  2  

 

CNBX Pharmaceuticals (PK) (USOTC:CNBX)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025 Plus de graphiques de la Bourse CNBX Pharmaceuticals (PK)
CNBX Pharmaceuticals (PK) (USOTC:CNBX)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025 Plus de graphiques de la Bourse CNBX Pharmaceuticals (PK)